Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

BACKGROUND AND OBJECTIVE: Lenvatinib showed promising results in a subgroup of patients with poorly differentiated thyroid carcinoma (PDTC) in the SELECT trial. Our aim was to report the effectiveness and tolerability of lenvatinib in our series of PDTC patients. METHODS: Medical records of eight co...

Descripción completa

Detalles Bibliográficos
Autores principales: Roque, João, Nunes Silva, Tiago, Regala, Catarina, Rodrigues, Ricardo, Leite, Valeriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083649/
https://www.ncbi.nlm.nih.gov/pubmed/36852694
http://dx.doi.org/10.1530/ETJ-23-0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083649/
https://www.ncbi.nlm.nih.gov/pubmed/36852694
http://dx.doi.org/10.1530/ETJ-23-0003

Ejemplares similares